News & Updates

Guselkumab yields durable benefit in biologic-naïve PsA patients
Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021

The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.

Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis
22 Nov 2021
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
13 Nov 2021

About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.

Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
13 Nov 2021